Salmonella Typhimurium Lipopolysaccharide (LPS) Antibody

Este producto es parte de LPS - Lipopolysaccharides
Product Graph
1261€ (1 mg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Salmonella Typhimurium Lipopolysaccharide (LPS) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx022225
tested applications
ELISA, IF/ICC, LF

Description

Salmonella Typhimurium Lipopolysaccharide (LPS) Antibody is a mouse monoclonal antibody against LPS from S. enterica subsp. enterica serovar Typhimurium.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Salmonella Typhimurium Lipopolysaccharide (LPS)
Host
Mouse
Reactivity
Bacteria
Recommended Dilution
Optimal dilutions/concentrations should be determined by the end user.
Clonality
Monoclonal
Conjugation
Unconjugated
Isotype
IgG2a
Purity
> 90% (SDS-PAGE)
Purification
Purified from ascites by Protein A chromatography.
Size 1
1 mg
Form
Liquid
Tested Applications
ELISA, IF/ICC, LF
Buffer
0.01 M PBS, pH 7.2, 0.1% NaN3. Does not contain stabilising proteins.
Availability
Shipped within 10-20 working days.
Storage
Aliquot and store at 2°C to 8°C upon receipt.
Dry Ice
No
Alias
LPS
Background
Antibody anti-LPS
Status
RUO
Note
Concentration: 3.5 mg/ml - 

Descripción

Lipopolysaccharides (LPS) are large molecules found in the outer membrane of Gram-negative bacteria, playing a crucial role in the structural integrity of bacterial cells and acting as a potent activator of the immune system. Composed of lipid A, a core oligosaccharide, and an O-antigen polysaccharide, LPS is a critical factor in bacterial pathogenicity. Lipid A is the bioactive component that triggers immune responses by binding to the Toll-like receptor 4 (TLR4) complex on immune cells, leading to the activation of nuclear factor-kappa B (NF-κB) and the release of pro-inflammatory cytokines such as IL-6 and TNF-alpha. While LPS is essential for host defense, its excessive activation can result in septic shock, characterized by systemic inflammation, organ failure, and high mortality. Therapeutic strategies targeting LPS-TLR4 signaling pathways are being explored to manage sepsis and other inflammatory conditions.

Related Products

EH4142

Human LPS IgG (lipopolysaccharide IgG) ELISA Kit

Ver Producto
EH4721

Human LPS IgM (lipopolysaccharide IgM) ELISA Kit

Ver Producto
EM2186

Mouse LPS (Lipopolysaccharides) ELISA Kit

Ver Producto